2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets

Based on Team Focus Group Skype Meeting on 11/30/2018

Rick Mandahl, Business Development

What does LBPI do that is game changing? I believe this is the most important question. All other questions help us get to this answer or illustrate the work that still lies ahead.

Aviva:

A. We curate contents in our FIVE DOMAINS of expertise in Scientific Media:

Pharmaceutical: Biologics, Small Molecules, Diagnostics
Life Sciences: Genomics and Cancer Biology
Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology: Metabolomics, Immunology
Biomedicine, BioTech, and MedTech (Medical Devices)
HealthCare: Patient-centered Medicine and Personalized/Precision Medicine

https://pharmaceuticalintelligence.com/

B. We published a BioMed e-Series in FIVE specialties of Medicine:

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

C. We developed a methodology to generate eProceedings of Medical and life Sciences Conferences in Real Time

Part Two: List of BioTech Conferences 2013 to Present

Marc Feldman:

The kind of curation that LPBI does is very rare and of broader use to professionals than pure tech lit. The “template” can be emulated across many fields

Stephen J. Williams:

The field of biomedical information has exploded in recent years, adding to problems related to informational overload, information loss, and informational bias. Through leveraging our developed methodology in co-curation, and technologic advances in social media, LPBI is reducing and eliminating this informational bias and offering a “new architecture for knowledge” and driving open innovation (see https://pharmaceuticalintelligence.com/2014/07/17/scientific-curation-fostering-expert-networks-and-open-innovation-lessons-from-clive-thompson-and-others/) which exceeds the level of the review or information collection (classifying data according to personal interest, personal insight) to the value driven by our curative process (curating information with critical thinking adding value to learner, multiple parties, added value to current knowledge base).

Indeed there are multiple specific examples located in our offerings, in which new information has been generated through our curative process

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

https://pharmaceuticalintelligence.com/2014/09/05/multiple-lung-cancer-genomic-projects-suggest-new-targets-research-directions-for-non-small-cell-lung-cancer/

https://pharmaceuticalintelligence.com/2015/06/03/therapeutic-implications-for-targeted-therapy-from-the-resurgence-of-warburg-hypothesis/

including leading to go/no go business decisions (to be discussed in meeting), resulting in curation an essential practice to manage open science and this new style of research.

In addition, the ability to rapidly disseminate scientific and medical information, as developed by our e-conference proceeding (see Dr. Lev Ari’s comment) and our site is of significant value as evidenced by our statistics and unique ability for analyses stemming from our curation methodology

https://pharmaceuticalintelligence.com/2017/05/06/case-studies-of-innovations-in-electronic-scientific-publishing-esp-marketing-econtent-curation-methodology-categories-of-research-functions-interdisciplinary-conceptual-innovations-by-cross-sec/

https://pharmaceuticalintelligence.com/2014/10/12/statistical-analysis-of-tweet-feeds-from-the-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-%E2%80%A2-congress-center-basel-sachs-associa/.

Irina:

Being able to search through curation and articles, allow easy access to information

Rick Mandahl:

How can LPBI support the move from fee for service to value based medicine. This is a topic across all of healthcare, and certainly of rising prominence with pharma.

Aviva:

By defining the boundaries of our domain of expertise to be I,II,III,IV,V, above we have declare the domains of knowledge we CREATE and CURATE contents to assist Providers to provide Value-based care. The adandonment of Fee for Service is a policy matter in the hands of American Medical Association who will ultimately, decided on One Payer System in its negotiations with the Health Insurance payors.

Marc:

Increasing the general knowledge of physicians and HC professionals can contribute eventually to cost reductions in terms of referrals. But this issue is more one of politics than science awareness

Stephen J. Williams:

As it currently stands there is no ‘direct’ ability for this platform to disrupt fee for service but as a source of curated information and the ability to expand clinical and scientific networks of experts this platform has much indirect value added to assist in the decision making process, not just by end clinicians but along the payer chain of decision makers.

Irina:

Act like an encyclopedia of updated information for physicians and health care professionals

Rick Mandahl:

HOW can LPBI content support the ongoing expansion of precision medicine methods?

LBPI content and methods should support the advance of precision medicine across every front that we address — but articulating the “HOW” from respected authorities (you) is an important step. We will circle back with Goldman Report at a later date.

Aviva:

Series B: Frontiers in Genomics Research

Series E: Patient-Centered Medicine

Marc:

In principle, the expansion of PM should be science based, and awareness of the science together with appropriate discussion of its clinical and translational value is important

Stephen J. Williams:

We have curated two series of e-books, Series B and Series E which are directly related to personalized medicine. These Two Series are constantly updated. As personalized medicine inherently heavily relies on constantly updated information, as well as analyses of the current and past literature, our platform, especially with regards to these two series and our e-conference coverage of the most influential international meetings on personalized medicine, supplies this branch of medicine with the most updated and most relevant insights into the topic, with the value added of including the vast network of experts in the field.

Rick Mandahl:

To what extent have Artificial Intelligence and Machine Learning techniques been applied or are envisioned as LBPI progresses?

Aviva:

Series B: Frontiers in Genomics Research

2019 – FORTHCOMING

· Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

Categories of Research in the Journal:

– Genome Biology Category = 641 articles

– Computational Biology/Bioinformatics = 441 articles

– AI =15 articles

Marc:

Ai methods are making some inroads into EHRs but this is in its infancy, and the same is triu on the use of genomics for chronic diseases

Stephen J. Williams:

Other than the planned upcoming ebooks and extensive conference coverage on the topic we do not have a plan for actively integrating a machine learning algorithm on our platform, however it is possible.

Irina:

AI methods would allow scientists to use LPBI as a search module for up to date information.

Rick Mandahl:

Scalability. Do we know of any limits to the number of users who can simultaneously access LBPI website? Have simulations or load tests been performed?

Aviva:

Bandwidth is Optimized by Hosting Vendor

SOE is done by WordPress.com

Stephen J. Williams

As of this point we have had a maximum of 3,000 unique users in a day but can not attest to how many individual users could access the site at one time. Please refer to Dr. Lev Ari for bandwidth and load test issues

Rick Mandahl

How do LPBI methods and content contribute to achieving “accurate diagnosis”? Is LBPI content robust enough to provide decision support in rendering a diagnosis? Illustrations, examples, anecdotes, testimonials will be important.

For more background on Dr. Li:

https://pharmaceuticalintelligence.com/2017/05/09/2017-raising-star-dr-dean-y-li-md-phd-vp-head-translational-medicine-merck/

Aviva:

Series A: e-Books on Cardiovascular Diseases –

Six volumes on diseases diagnosis and treatments

Marc:

Insofar as more general knowledge is helpful in diagnostics, LPBI makes that knowledge more accessible. It also gives an interpretable sense of what the specialists know and regard as important for diagnosis.

Stephen J. Williams:

In my view, LPBI was never meant to provide for a clinical diagnosis, but could offer informational support in this regards.

Irina:

LPBI makes information accessible as a form of Wikipedia

Rick Mandahl:

For many years the issue of “research productivity” has been an issue in pharma. How does, or how might LBPI methods and content contribute to improved research productivity? IIlustrations, examples, anecdotes, testimonials would be helpful

Aviva:

The contents of LPBI Group’s Journal (5,400 scientific articles, e-Readers 1.5 million),

Journal Ontology (640 Categories of Research) – organize the domain knowledge I,II,III,IV,V, above, BioMed e-Series 16 volume, Each volume consists of ~100 artcles

electronic Table of Contents of contribute to research productivity in the subject matter of each e-book

Marc:

Research productivity is improved through saving time by reading LPBI’s curations and thence deciding what literature is important to follow up.

Stephen J. Williams:

The power and support of this curation methodology may be summed up in the following posts (https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/

and in our Praising LBPI tab at https://pharmaceuticalintelligence.com/praising-lpbi/. In addition curations of comments on specific article curations include

https://pharmaceuticalintelligence.com/2013/09/04/issues-in-personalized-medicine-discussions-of-intratumor-heterogeneity-from-the-oncology-pharma-forum-on-linkedin/

where our curations had led to very involved discussions with worldwide leaders in the respective fields. In addition, several ideas for startups have been spring-boarded by this curative process (will be discussed in meeting).

The issue of research productivity has been of great concern, and one area that has hampered productivity is the validation of past results and literature findings. This has been at the forefront of my mind during the development of this curative process. In this regard I have initiated this conversation that curation methodology as the faster, more efficient process to validate past and current results

https://pharmaceuticalintelligence.com/2014/07/17/scientific-curation-fostering-expert-networks-and-open-innovation-lessons-from-clive-thompson-and-others/)

and in

https://pharmaceuticalintelligence.com/2015/10/26/a-curated-history-of-the-science-behind-the-ovarian-cancer-%CE%B2-blocker-trial/

in which I take a finding from years ago to determine how past research aligns with current findings and in particular, if questions which eliminate from past research is methodically answered in future research using unbiased literature analysis. This is an area of ongoing personal research and a basis for future curations.

Irina:

LPBI curations allows scientists to get preliminary information prior to searching in databases like Pubmed

Gail Thornton, Marketing Communications

What is the overall strategic goal of LPBI?

Aviva:

Publish in 2018, CVD, Volume 5 & 6
Publish in 2019, Genomics Volume 2 on NGS
Prospect for potential acquirer of the Intellectual Property of LPBI Group – orchestrate a successful EXIT in 12/2019.
Successfully transfer ownership of the IP, including training of new teams
Get Contracts with Acquirer for all Team member interested to continue the work with the new Owner
Attain a fair market value for three assets:

– 5400 Articles – 2500 Journal Subscribers, Journal Ontology, Tags, Scientific Comments

– 16 Volumes of e-Books on Amazon.com

– Archive of +60 Conferences eProceedings

Distribute all proceeds to parties involved in

– Managing the transaction and transfer of IP Ownership

– all content CREATORS: Experts, Authors, Writers (EAW)s and e-Book Editors based on the “proportional FORMULA” applied to all articles selected for inclusion in e-Books

– consider expenses to produce and promote the e-Books: Format Conversion Agreements as expenses and Cover Page Flyers production

– consider all Royalties paid by Amazon.com

– consider all Income Taxes paid on Royalties deposited by Amazon.com into LPBI Group bank account

Consider launch a SoundCloud – Audio Series on Interviews with Distinguished MDs
Consider Special Volumes per Customer Order

Marc:

There are two meanings to strategy: 1. Ownership transfer. 2. Making the best possible curations and books that can maximally benefit HC professionals.

Stephen J. Williams:

I am going to refer to Dr. Lev Ari’s answers on this topic. Our initial goal had been to create a platform to disseminate scientific and medical information in web based and e-book formats. This was achieved by producing a network of experts in various disciplines who contribute to the site/series volume as writers, authors, and editors, with added input from the scientific/medical community through a social-media based platform. A discussed exit strategy has involved sale of ebooks on Amazon targeted to professionals and professional organizations or sale of the platform to an outside party.

Irina:

To transfer the information and make it accessible to scientists.

Gail:

What are your organization’s strengths?

1. Key Opinion Leadership by Team members

https://pharmaceuticalintelligence.com/contributors-biographies/

2. Leadership of Director and Founder: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/founder/

– 7,000 BioTech Connections on LinkedIn

– https://www.linkedin.com/in/avivalevari/

– Endorsements on LinkedIn – Click to see Names

Industry Knowledge

1. Data Analysis

See 190 endorsements for Data Analysis99+

2. Medical Devices

See 162 endorsements for Medical Devices99+

3. Start-ups

See 131 endorsements for Start-ups99+

4. Clinical Research

See 127 endorsements for Clinical Research99+

5. Clinical Trials

See 110 endorsements for Clinical Trials99+

6. Analytics

See 100 endorsements for Analytics99+

7. Product Management

See 97 endorsements for Product Management97

8. Healthcare

See 89 endorsements for Healthcare89

3. Leadership of Content Consultant for e-Series A, B,C,D,E and Co-Editors of 16 volumes

https://pharmaceuticalintelligence.com/contributors-biographies/senior-editors/

4. DOMAIN EXPERTISE of PhDs, MDs, MD/PhDs, PharmD

https://pharmaceuticalintelligence.com/contributors-biographies/

5. Members of the Board, Scientific reputation

https://pharmaceuticalintelligence.com/contributors-biographies/members-of-the-board/

6. 2012 – 2017 represented record productivity in generation od Scientific Curations: +5,000 articles and e-Book publishing of THIRTEEN e-Books, some +2,000 pages

7. Top Posts for all days ending 2018-11-21 (Summarized)

All time

Home page by Views: 584,551

#1 article by Views: 16,606

#2 article by Views: 12,992

#3 article by Views: 11,329

#4 article by Views: 11,246

#5 article by Views: 6,845

Top Authors for all days ending 2018-11-21 (Summarized)

All time

Author & Views
2012pharmaceutical – 386,608 Views
larryhbern – 283,434 Views
tildabarliya – 58,283 Views
Stephen J. WIlliams – 51,060 Views
Dror Nir – 30,674 Views

Marc:

The team of experts who can do first rate curation in many subfields of medicine.

Stephen J. Williams:

Our team of dedicated experts, authors and editors
strong communication between the members
The rapid and enthusiastic response from the scientific/medical community on the quality of our work as evidenced by the commentary and reviews and site statistics.

Irina:

The diverse team of scientists and physicians that write curations and report on new scientific data

Gail:

What makes LPBI unique and different from other similar organizations/businesses?

Aviva:

Innovations in the following domains:

Multi-Authoring Platform on WordPress.com – all websites are one person’s blog
Curation Methodology combats: Explosion of knowledge in the Life Sciences and Medicine
Clinical Interpretation of basic research findings published in top peer reviewed Journals
Usage of Journal Ontology to create electronic Table of Contents (eTOCs) for e-Books
Constant Updates of Journal’s articles combats: Information Obsolescence
Conferences covered in real time stimulate new subjects for articles in the Journal
Journal, Books, Conferences – Three INTERCONNECTED businesses
AGORA – Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/

Marc:

The templates and quality of the curation, together with continual updating

Stephen J. Williams:

We offer analysis from experts within the field not just reporting as some sites do. In addition, due to our methodology of curation this knowledge base we create is constantly updated with new analysis.

Our unique ontology makes search seamless as well as contributes to our SEO strategy, unlike keyword strategies other sites use.

Our conference coverage uses multiple social platforms to increase awareness and distribution of material and in particular integrates posts and additional information other than just small snippets of coverage

Irina:

Continual updating of the information by the members and the easily accessible template.

Gail:

How has the role of the patient — and physician — changed over the past five years — and what has been your role in uniting them through your work with LPBI?

Aviva:

Series E: Patient-Centered Medicine – Was Launched in 2012 before the term was coined !!!!!!!!!

Patient and physicians relationships are discussed in each volume:’

Marc:

Patients have different expectations and in many cases more knowledge today as medicine becomes more media savvy and media oriented. People are demanding more of physicians but medicine in general needs a different set of communication tools to keep up with this demand.

Stephen J. Williams:

This can be seen in our e-book series E on patient centered medicine. In addition there has been lively discussions through our site.

Irina:

Patients can have an idea how to communicate with physicians and also be familiar with what other people go through.

Gail:

Why are you looking for an exit strategy?

Aviva:

CSO is on indefinite medical leave
All Goals attained had exceeded expectations – obligation to compensate all contributors to the Venture
Wish to venture into writing in different STYLE: Biographies of Scientists and an autobiography of myself

Marc and Irina:

It is about time

Stephen J. Williams:

I feel an exit is a natural strategy at this point. To grow LPBI would require, at this point, much capital.

Amnon Danzig, Strategy

What are the “pains” at the eco-system that LPBI Group will cure?

Aviva:

Information Explosion
Information Obsolescence

Marc:

Keeping up with the literature as the number of journals increases, but the quality of research becomes more variable. Sorting the wheat from the chaff.

Stephen J. Williams:

informational overload
informational bias
information validation
scientific communication “breaking down the silos” (please see my post on breaking down silos)

Irina:

Sorting out what its there but also keeping updated the information that has been curated and reported on.

Amnon:

What are strategic challenges for LPBI Group?

Aviva:

IF full employment THEN hard to get Scientists to write on a volunteer basis
Training new EAWs

Marc:

Before exit, keeping high quality professionals interested and involved.
After exit, the acquirer will need professional editors and HC professionals to work hand-in-hand

Stephen J. Williams:

I agree that keeping a volunteer ‘staff’ is very hard and as most of the work is time consuming, it is very difficult to maintain the quantity of material as we had done in the past. (compare site stats now versus 2012)

Irina:

To find new people who are willing to volunteer their time to write

Amnon:

What represent the “perfect” acquirer in terms of:

Platforms
Capacity
Distinguish capabilities

Aviva:

– Content syndicators like e-Scientific Publishers
– Clarivate Analytics – Reuters
– KKR – Internet Brands under one roof
– big Pharma
– Medical Associations of Countries as Japan, Brazil, European Countries

Marc:

I speculate that Indian or Chinese organizations that have upwardly mobile clientele and expanding needs in high quality HC delivery might be interested in publishing the kind of material that charactertizes LPBI’ output

Stephen J. Williams:

Google Verily
Informatics company

Irina:

Countries with non accessible scientific information

Amnon:

What is the ultimate business model for the acquirers?

Aviva:

– Sell Service based on our Contents

https://clarivate.com/blog/tag/thomson-reuters/

Marc:

Almost like a magazine for all HC professionals that makes the latest medical and related scientific advances digestible and palatable.

Stephen J. Williams:

-Analytics of e-readers
-informatics for decision makers (healthcare, payers, pharma M&A strategists)

PARTIES OF POTENTIAL INTEREST IN LPBI GROUP’S IP

Aviva:

Reuters’ Clarivate Analytics
KKR
Google Life Sciences, Verily
Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries

Stephen J. Williams:

Medscape
Clarivate
Google Life Sciences
Life science consulting firms

Amnon’s List:

Medscape

Part of Internet Brands (www.internetbrands.com)

Owned by KKR and Temasek

Better website: user-friendly and intuitive.

Medscape Strategic Potential Perspectives:

Good fit:
Do not own this type of activities.
Can gain more focused means.
Network effect?
The same technologies can be spread to their other businesses.

LPBI Group perspectives:

Much larger audience – the same distinctive capabilities can serve more segments.
Do not need to prove profitable business model
Can carry LPBI Group with more resources.

Potential Customers: